The effect of spinal cord-injury level on the outcome of neurogenic bladder treatment using OnabotulinumtoxinA

Urology Annals

Volumn 7, Issue 3, 2015, Pages 320-324

  Al Taweel, Waleed ^a   Alzyoud, Khalil Mohammed ^b  

^a ALFAISAL UNIVERSITY   (Saudi Arabia)

^b Prince Sultan Military Medical City   (Saudi Arabia)

Author keywords

Neurogenic bladder; OnabotulinumtoxinA; overactive; spinal cord injury

Indexed keywords

BOTULINUM TOXIN A; OXYBUTYNIN; TOLTERODINE;

ADULT; ARTICLE; BLADDER CAPACITY; BLADDER FUNCTION; CERVICAL SPINE INJURY; CLINICAL EXAMINATION; CYSTOMETRY; CYSTOSCOPY; DETRUSOR MUSCLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FEMALE; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUSCLE WEAKNESS; NEUROGENIC BLADDER; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENCE RISK; SPINAL CORD INJURY; SPINE INJURY; TREATMENT OUTCOME; URGE INCONTINENCE; URINALYSIS; URINARY TRACT INFECTION; URODYNAMICS; VISUAL ANALOG SCALE;

EID: 84938517363     PISSN: 09747796     EISSN: 09747834     Source Type: Journal    
DOI: 10.4103/0974-7796.152013     Document Type: Article

References (30)

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37-49.
2. Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California medicaid program. Value Health 2005;8:495-505.
3. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: An update of a systematic review and meta-analysis. Eur Urol 2008;54:543-62.
4. van Ermengem E. A new anaerobic bacillus and its relations with the botulism. Zeitsch Hyg Infekt 1897;26:1-56.
5. Montecucco C, Schiavo G. Structure and function of tetanus and botulinum neurotoxins. Q Rev Biophys 1995;28:423-72.
6. Chapple C, Patel A. Botulinum toxin-New mechanisms, new therapeutic directions? Eur Urol 2006;49:606-8.
7. Stohrer M, Schurch B, Kramer G, Schmid D, Gaul D, Hauri D. Botulinum A toxin inthe treatment of detrusor hyperreflexia in spinal cord injury. A new alternative tomedical and surgical procedures? Neurourol Urodyn 1999;18:401-2.
8. Karsenty G, Denys P, Amarenco G, De Seze M, Gamé X, Haab F, et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: A systematic literature review. Eur Urol 2008;53:275-87.
9. Giannantoni A, Mearini E, Di Stasi SM, Costantini E, Zucchi A, Mearini L, et al. New therapeutic options for refractory neurogenic detrusor overactivity. Minerva Urol Nefrol 2004;56:79-87.
10. Reitz A, Stöhrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004;45:510-5.
11. Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 2006;68:1193-7.
12. Schulte-Baukloh H, Schobert J, Stolze T, Stürzebecher B, Weiss C, Knispel HH. Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: An objective and subjective analysis. Neurourol Urodyn 2006;25:110-5.
13. Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 2006;49:528-35.
14. Giannantoni A, Di Stasi SM, Nardicchi V, Zucchi A, Macchioni L, Bini V, et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol 2006;175:2341-4.
15. Kuo HC. Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions. Urology 2006;67:232-6.
16. Smith CP, Nishiguchi J, O'Leary M, Yoshimura N, Chancellor MB. Singleinstitution experience in 110 patients with botulinum toxin A injection intobladder or urethra. Urology 2005;65:37-41.
17. Hajebrahimi S, Altaweel W, Cadoret J, Cohen E, Corcos J. Efficacy of botulinum-A toxin in adults with neurogenic overactive bladder: Initial results. Can J Urol 2005;12:2543-6.
18. Gaillet S, Bardot P, Bernuz B, Boissier R, Lenne-Aurier K, Thiry-Escudier I, et al. Five years follow-up study and failures analysis of Botulinum toxin repeated injections to treat neurogenic detrusor overactivity. Prog Urol 2012;22:1064-70.
19. Sussman D, Patel V, Del Popolo G, Lam W, Globe D, Pommerville P. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn 2013;32:242-9.
20. Krhut J, Samal V, Nemec D, Zvara P. Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: A pilot study. Spinal Cord 2012;50:904-7.
21. Schäfer W, Abrams P, Liao L, Mattiasson A, Pesce F, Spangberg A, et al. Good urodynamic practices: Uroflowmetry, filling cystometry, and pressureflow studies. Neurourol Urodyn 2002;18:261-74.
22. Wefer B, Ehlken B, Bremer J, Burgdörfer H, Domurath B, Hampel C, et al. Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany. World J Urol 2010;28:385-90.
23. Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: A randomized, double-blind trial. J Urol 2011;185:2229-35.
24. Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomised, double-blind, placebocontrolled trial. Eur Urol 2011;60:742-50.
25. Bakke A, Vollset SE. Risk factors for bacteriuria and clinical urinary tract infection in patients treated with clean intermittent catheterization. J Urol 1993;149:527-31.
26. Sauerwein D. Urinary tract infection in patients with neurogenic bladder dysfunction. Int J Antimicrob Agents 2002;19:592-7.
27. Mouttalib S, Khan S, Castel-Lacanal E, Guillotreau J, De Boissezon X, Malavaud B, et al. Risk of urinary tract infection after detrusorbotulinum toxin A injections for refractory neurogenic detrusor overactivity in patientswith no antibiotic treatment. BJU Int 2010;106:1677-80.
28. Ehren I, Volz D, Farrelly E, Berglund L, Brundin L, Hultling C, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: A randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol 2007;41:335-40.
29. Schurch B, de Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: Results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005;174:196-200.
30. Chancellor MB, Patel V, Leng WW, Shenot PJ, Lam W, Globe DR, et al. OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity. Neurology 2013;81:841-8.